In the realm of AI-driven trading robots, the Swing trader: Deep Trend Analysis v.2 (TA) has emerged as one of the standout performers in our robot factory. Over the previous week, this particular AI trading robot showcased its prowess by generating a remarkable 3.42% gain through its strategic trading of BNGO. However, as we delve deeper into the technical indicators and earnings results, it becomes evident that a price pull-back may be on the horizon.
BNGO, the stock in focus for the Swing Trader AI robot, currently exhibits an interesting technical signal. The Stochastic Oscillator, a popular momentum indicator, has remained in the overbought zone for a continuous period of 1 day. This situation suggests that the stock may have experienced a rapid price increase and could be due for a correction. Traders and investors should interpret this as a cautionary sign, indicating a potential downward movement in the near future.
Analyzing the recent earnings report of BNGO, which was released on May 09, we find that the company reported earnings per share (EPS) of -10 cents. Although the reported EPS matched the estimate of -10 cents, it is worth noting that the earnings remained in the negative territory. With 15.56 million shares outstanding, the current market capitalization of BNGO stands at 243.59 million dollars.
The negative earnings per share figure indicates that the company incurred a loss during the reported period. Investors and traders should be aware of the potential impact of this loss on the stock's future performance.
While the Swing trader: Deep Trend Analysis v.2 (TA) AI trading robot has demonstrated its capability to generate impressive gains through its strategic trading of BNGO, the presence of the Stochastic Oscillator in the overbought zone suggests a potential price pull-back in the near future. Additionally, the recent earnings report showed a negative EPS, emphasizing the importance of carefully assessing the financial health of the company.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BNGO advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 71 cases where BNGO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on June 06, 2025. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on June 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BNGO as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
BNGO moved below its 50-day moving average on May 28, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNGO crossed bearishly below the 50-day moving average on May 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.597) is normal, around the industry mean (24.242). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.993) is also within normal values, averaging (42.497).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of technologies for analysis of large biological molecules
Industry MedicalSpecialties